Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular Disease (AI-CVD): Multicenter Retrospective Study

NCT07856472 · tracked via the Priya Life Science South Korea tracker
Phase
Observational
Started
2023-03-01
Last updated
2026-10-02

Condition(s) studied

Cardiovascular DiseasesCoronary Artery DiseaseHeart FailureAtrial Fibrillation (AF)Ventricular Hypertrophy

Investigational drug(s) / intervention(s)

Retrospective ECG Data Analysis

Retrospective ECG Data Analysis: Analysis of de-identified 12-lead electrocardiogram raw data using deep learning models for cardiovascular disease diagnosis and prognosis.

Study summary

This multicenter retrospective study aims to develop, validate, and clinically apply an artificial intelligence (AI)-powered electrocardiography (ECG) algorithm for the diagnosis and prognostic prediction of cardiovascular diseases, including coronary artery disease and heart failure. By utilizing encrypted raw 12-lead ECG text data and deep neural network models, the study evaluates the effectiveness of AI-enhanced ECG in detecting cardiac abnormalities and predicting clinical outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 years or older diagnosed with cardiovascular diseases, including coronary artery disease and heart failure. * Patients with 12-lead electrocardiogram (ECG) records extractable as text (XML Exclusion Criteria: \- Patients deemed inappropriate as study subjects by the investigator's judgment

Primary outcome measure(s)

  • Diagnostic Performance (AUC-ROC) of AI-ECG Models — Baseline
    To evaluate the area under the receiver operating characteristic curve (AUC-ROC) of the deep neural network-based 12-lead ECG model for diagnosing cardiovascular diseases compared to reference clinical standards.

Trial sites (1)

FacilityCityRegionStatus
Inha University Hospital Incheon Incheon Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07856472 on ClinicalTrials.gov ↗ ← All trials in South Korea